Human CYP3A is the most abundant P450 isozyme present in the human liver and small intestine, and metabolizes around 50% of medical drugs on the market. The human CYP3A subfamily comprises four members (CYP3A4, CYP3A5, CYP3A7, CYP3A43) encoded on human chromosome 7. However, transgenic mouse lines carrying the entire human CYP3A cluster have not been constructed because of limitations in conventional cloning techniques. Here, we show that the introduction of a human artificial chromosome (HAC) containing the entire genomic human CYP3A locus recapitulates tissue-and stage-specific expression of human CYP3A genes and xenobiotic metabolism in mice. About 700 kb of the entire CYP3A genomic segment was cloned into a HAC (CYP3A-HAC), and trans-chromosomic (Tc) mice carrying a single copy of germline-transmittable CYP3A-HAC were generated via a chromosome-engineering technique. The tissue-and stage-specific expression profiles of CYP3A genes were consistent with those seen in humans. We further generated mice carrying the CYP3A-HAC in the background homozygous for targeted deletion of most endogenous Cyp3a genes. In this mouse strain with 'fully humanized' CYP3A genes, the kinetics of triazolam metabolism, CYP3A-mediated mechanism-based inactivation effects and formation of fetal-specific metabolites of dehydroepiandrosterone observed in humans were well reproduced. Thus, these mice are likely to be valuable in evaluating novel drugs metabolized by CYP3A enzymes and in studying the regulation of human CYP3A gene expression. Furthermore, this system can also be used for generating Tc mice carrying other human metabolic genes. †
INTRODUCTION
Cytochrome P450 enzymes (CYPs) are responsible for the oxidative metabolism of a diverse range of xenobiotics, including therapeutic drugs, carcinogens, toxicants and endogenous compounds such as steroid hormones and bile acids (1, 2) . In particular, CYP3A enzymes have central roles in the first-pass metabolism of more than half of currently available therapeutic drugs because of abundant expression in the liver and intestine (3) . Among the human CYP3A subfamily, the expression profiles of CYP3A4 and CYP3A7 are distinct with respect to developmental perspectives (4, 5) . CYP3A7 is detected as early as 50 -60 days after the start of gestation and persists until after birth, when its abundance decreases over the first months of life. Conversely, CYP3A4 is not detectable before birth, but gradually increases in expression with postnatal age. In addition, CYP3A enzymes are induced and/or inhibited by various drugs. Therefore, CYP3A enzymes are significant determinants of drug bioavailability and drug -drug interactions (DDIs). This is a particular concern in the development of new drugs because many drugs are used in combination therapies, which sometimes lead to serious DDIs (6) .
Given the importance of CYP3A, in vitro studies using human liver microsomes, human hepatocytes, cDNA-expressed enzymes, cell-based cultures and reporter vector systems have been initiated in preclinical development of drugs to examine whether the candidates are substrates, inhibitors and/or inducers for CYP3A (7) . In general, experimental animals (especially rodents) have been used as in vivo models to predict pharmacokinetics and toxicity in humans. However, results obtained in in vitro studies as well as in in vivo studies using experimental animals do not always reflect pharmacokinetics in humans (8) . DDIs arising from irreversible inhibition of CYP3A via mechanism-based inactivation (MBI) often cause serious adverse drug reactions (6) . Compared with the prediction of human pharmacokinetics using animals, less effort has been directed toward predicting clinical DDIs in in vivo experimental animal models because of substantial species differences in the inhibitor sensitivities of CYP3A (9, 10) .
In one approach to overcome the problems of species differences in CYP3A enzymes between humans and experimental animals, transgenic mouse lines carrying the specific human CYP3A isoform have been constructed (11) (12) (13) (14) (15) (16) . Although the human CYP3A subfamily consists of four members (CYP3A4, CYP3A5, CYP3A7 and CYP3A43) encoded on a 700 kb locus on human chromosome 7 (hChr.7), transgenic mouse lines carrying the entire human CYP3A cluster have not been constructed because of limitations of conventional cloning techniques in transferring many genes at one time. We recently developed cloning techniques for megabase-sized genes, using human artificial chromosome (HAC) vectors (17, 18) . HACs exhibit several important characteristics desired for ideal gene-delivery vectors. These include stable episomal maintenance and the capacity to carry large genomic loci with their regulatory elements, thereby allowing physiological regulation of the introduced gene in a manner similar to that of the native chromosome (19) .
In the present study, we generated a trans-chromosomic (Tc) mouse line with the HAC containing the entire human CYP3A cluster (designated CYP3A-HAC) and an endogenous mouse Cyp3a cluster knockout (KO) mouse line with the CYP3A-HAC (designated CYP3A-HAC/Cyp3aKO), using chromosome-engineering techniques. We also evaluated the retention of the CYP3A-HAC, tissue-and stage-specific expression (mRNA, protein and enzymatic function) of the CYP3A enzymes. Our novel humanized CYP3A mice showed the expected xenobiotic metabolism resulting in humanized patterns, e.g. MBI.
RESULTS

Generation of CYP3A-HAC mice
To generate 'humanized' Tc mice with the entire human CYP3A cluster (CYP3A4, CYP3A5, CYP3A7 and CYP3A43), a HAC containing the CYP3A cluster was constructed using the Cre/ loxP-mediated megabase-sized gene-cloning system (Fig. 1A) . First, mouse A9 cells containing a hChr.7, which were produced via microcell-mediated chromosome transfer (MMCT) (20, 21) , were screened by polymerase chain reaction (PCR) analyses using hChr.7-specific primers (data not shown), and the hChr.7 was transferred to homologous recombination-proficient chicken DT40 cells via MMCT. Since CYP3A5 is a polymorphically expressed gene in the CYP3A cluster (22) , singlenucleotide polymorphisms of CYP3A5 was determined in the DT40 cells containing the hChr.7. PCR-restriction fragmentlength polymorphism analyses showed that the CYP3A5 gene on the hChr.7 was inactive type, CYP3A5 * 3 (data not shown). In this study, hChr.14-derived HAC (designated SC20-HAC) vector was used for the cloning of the CYP3A cluster, since our previous study showed that the SC20-HAC and the derivative l-HAC were stably maintained in mouse embryonic stem (ES) cells and in mice (17) . To clone 700 kb of the CYP3A cluster on hChr.7 into the HAC, the hChr.7 was truncated at the AF006752 locus and a loxP sequence was introduced into the AC004922 locus on the hChr.7 in DT40 cells (23) . With the targeting construct pBS-TEL/AF006752 Puro, for the telomere-associated chromosomal truncation at the AF006752 loci on hChr.7, 15 of 145 drug-resistant clones selected in the presence of puromycin were targeted correctly, as shown by Southern blotting (designated hChr.7-DAF006752) (Supplementary Material, Fig. S1A and B) . Fluorescence in situ hybridization (FISH) analyses showed that the targeting construct was integrated into the correct locus on the hChr.7 in DT40 cells ( Fig. 1B and C) . With the targeting construct pAC004922-loxP-Hyg, for the cloning site (loxP) and positive selection (hygromycin), 36 of 96 drug-resistant clones selected in the presence of hygromycin and puromycin were targeted correctly, as shown by PCR and Southern blotting (designated hChr.7-DAF006752-loxP) (Supplementary Material, Fig. S2A and B). FISH analyses showed that the targeting construct was integrated into the correct locus on the hChr.7-DAF006752 in DT40 cells (Fig. 1D ). The DT40 (hChr.7-DAF006752-loxP) cells and DT40 cells containing the HAC with loxP (R56 clone) were fused and selected by blasticidin S and hygromycin to obtain the hybrid DT40 clones with two different human chromosomes: the HAC and the modified hChr.7. To induce the reciprocal translocation between the HAC and modified hChr.7, the Cre expression Human Molecular Genetics, 2013, Vol. 22, No. 3 579
vectors were transfected to the DT40 hybrids; GFP-positive fractions were then sorted by fluorescence-activated cell-sorting (FACS) analyses to collect the recombinants. FISH analyses showed that the defined region of hChr.7 containing the CYP3A cluster was cloned into the HAC vector in the DT40 hybrid cells (designated DAF006752-HAC) (Fig. 1E-G) . The DAF006752-HAC was then introduced into mouse ES cells via Chinese hamster ovary (CHO) cells, using MMCT. FISH analyses showed that the HAC was independently maintained in the host chromosome ( Fig. 1H and I ). Chimeric mice were produced from the TT2F (DAF006752-HAC) lines, and chimeras with various forms of coat-color chimerism were successfully obtained. However, germline transmission was not observed from the TT2F (DAF006752-HAC)-derived chimeras (data not shown). Thus, we attempted to truncate the DAF006752-HAC at the AC073842 locus because several genes are located between the AF006752 loci and the CYP3A cluster. The DAF006752-HAC was transferred to DT40 cells from the CHO (DAF006752-HAC) cells, and then we truncated the DAF006752-HAC at the AC073842 locus (Fig. 1A) . With the targeting construct pBS-TEL/DAC073842 HisD, for the telomere-associated chromosomal truncation at the AC073842 loci on the DAF006752-HAC, 9 of 433 drug-resistant clones selected in the presence of L-histidinol and hygromycin were targeted correctly, as shown by PCR (designated CYP3A-HAC) (Supplementary Material, Fig. S3 ). The CYP3A-HAC was then introduced into mouse ES cells via CHO cells using MMCT, and karyotypically normal ES clones were used for chimeric production. Chimeric mice were produced from the TT2F (CYP3A-HAC) lines, and chimeras with various forms of coat-color chimerism were successfully obtained. The germline transmission was confirmed by PCR analyses in the four chimeric mice with 100% coat-color chimerism. The littermates were further mated with wild-type (WT) mice. The mice were used for expression analyses described below using several tissues. , DT40 (hChr.7-DAF006752), DT40 (hChr.7-DAF006752-loxP), DT40 (HAC), DT40 (HAC+ hChr.7-DAF006752-loxP), DT40 (DAF006752-HAC), CHO (DAF006752-HAC) and ES (DAF006752-HAC). Digoxigenin-labeled human COT-1 DNA (red) was used to detect the HAC. Biotin-labeled PGK-Puro and PGK-Hyg (green) were used to detect the marker gene on the HAC in (C) and (D), respectively. The hChr.14 (red)-and hChr.7 (green)-specific painting probes were used to detect the DAF006752-HAC (F and G). The insets show an enlarged image of the DAF006752-HAC (arrow). Chromosomal DNA was counterstained with DAPI.
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Retention of CYP3A-HAC and expression of CYP3As
PCR and FISH analyses were undertaken to determine whether the genomic region of the human CYP3A cluster was retained and how many cells had the CYP3A-HAC in various tissues of Tc mice with the CYP3A-HAC. PCR analyses using primers for the detection of CYP3A4, CYP3A5 and CYP3A7 showed that all tissues contained the CYP3A region on the HAC (Fig. 2A) . FISH analyses showed that the CYP3A-HAC was present as an individual chromosome in Tc tail fibroblast cells (Fig. 2B) , and that the CYP3A-HAC was detected in ≥85% of cells in the liver, intestine, kidneys, lungs, heart, brain and uterus (Fig. 2C) . Retention of the HAC was relatively lower in the spleen than in other tissues, which is consistent with previous observations (24) . Next, to determine whether genes on the CYP3A-HAC were expressed, reverse transcription-PCR (RT-PCR) analyses were carried out in various tissues of adult Tc mice and in the livers of Tc mice of different ages. CYP3A4 was expressed in the liver and small intestine; CYP3A5 was expressed in the liver, small intestine, kidney, lung and uterus; and CYP3A43 was expressed in the liver, small intestine and kidney (Fig. 2D ). In the livers of Tc mice of different ages, CYP3A4 and CYP3A5 were highly expressed after birth, and CYP3A7 was highly expressed before birth (Fig. 2E ). These data suggest that genes on the CYP3A cluster were expressed in a tissue-specific and developmental-specific manner, which was consistent with the expression profile in humans (25, 26) .
Induction of CYP3A4 in the livers
To ascertain whether the expression of human CYP3A genes can be induced in a mouse genetic background through mousederived transregulatory factors such as pregnane X receptor (Pxr), Hnf4alpha or Car, Tc mice containing the CYP3A-HAC were treated with pregnenolone-16alpha-carbonitrile (PCN), clotimazole, rifampicin or a solvent (corn oil). RT-PCR analyses showed that CYP3A4 mRNA expression in the livers of PCN-, clotrimazole-or rifampicin-treated Tc mice was higher than that of solvent-treated Tc mice (Supplementary Material, Fig. S4 ). Quantitative RT-PCR analyses showed that the CYP3A mRNA expression in PCN-treated Tc mice was 4-fold higher than that in rifampicin-treated Tc mice (data not shown). These data were consistent with reports that PCN induces mouse CYP3A via mouse Pxr-mediated gene regulation. Although rifampicin is known to be a humanspecific inducer, .20 mg/kg of rifampicin could induce mouse CYP3A via mouse Pxr (27, 28) . These data suggest that genomic regions on the CYP3A-HAC contained xenobioticresponsive elements, and that the induction of CYP3A4 may be mediated by endogenous mouse Pxr.
Generation of CYP3A-HAC/Cyp3aKO mice
To generate Cyp3aKO mice lacking the mouse Cyp3a cluster, Cyp3a13KO lines and Cyp3a57-59KO lines were generated and the two lines were mated. The size between the Cyp3a57-59 gene cluster and a Cyp3a13 gene is 5 Mb, and several genes are located between the loci; so the two KO lines were generated independently. First, Cyp3a57-59KO ES lines were generated. With the targeting construct loxP3aUP, for the first loxP site at the Cyp3a57 loci on mChr.5, 2 of 392 drug-resistant clones selected in the presence of G418 were targeted correctly in mouse ES cells as assessed by Southern blotting (data not shown) (Supplementary Material, Fig. S5A ). With the targeting construct loxP3aDOWN, for the second loxP site at the Cyp3a59 loci on the first loxP-targeted mChr.5, 3 of 348 drug-resistant clones selected in the presence of puromycin were targeted correctly in mouse ES cells as assessed by Southern blotting (data not shown) (Supplementary Material, Fig. S5B ). To induce the deletion between Cyp3a57 and Cyp3a59, the Cre expression vectors were transfected to the double-loxP-targeted ES clones, and then GFP-positive fractions were sorted by FACS (Supplementary Material, Fig. S5C ). PCR analyses showed that the defined region of the mChr.5 containing the mouse Cyp3a cluster was deleted in mouse ES cells. Second, Cyp3a13KO ES lines were generated independently of Cyp3a57-59KO mouse ES lines. With the targeting construct loxP3a13, for the deletion of Cyp3a13 on mChr.5, 5 of 60 drug-resistant clones selected in the presence of G418 were targeted correctly in mouse ES cells as assessed by PCR and Southern blotting (data not shown) (Supplementary Material, Fig. S6A ). Chimeric mice were produced from Cyp3a57-59KO ES lines and Cyp3a13KO ES lines, and the germline transmission was confirmed in chimeric mice with 100% coat-color chimerism by PCR analyses. F1-to-F3 mice were further mated to generate Cyp3a57-59 clusterand Cyp3a13-double KO mice (designated Cyp3aKO mice) for the following expression analyses. Furthermore, Cyp3aKO mice were mated to CYP3A-HAC mice to generate CYP3A-HAC/Cyp3aKO mice, which contained the CYP3A-HAC and deleted the mouse Cyp3a cluster. The germline transmission efficiency of CYP3A-HAC in the Cyp3aKO background was 30% (data not shown), which was comparable with the previous study (29) . To investigate whether the expression on the Cyp3a cluster gene was lost, RT-PCR analyses were completed with the livers of the Cyp3aKO mice, employing mouse Cyp3a and human CYP3A primers after genomic PCR analyses using tail DNA (Supplementary Material, Table S1 ). RT-PCR analyses showed that the genes on the mouse Cyp3a cluster were expressed in the livers of WT mice but not in those of Cyp3aKO and CYP3A-HAC/Cyp3aKO mice, and that human CYP3A4 on the CYP3A-HAC was expressed only in the livers of CYP3A-HAC/Cyp3aKO mice (Fig. 3A) . These data suggest that the CYP3A-HAC was successfully transferred to the mouse Cyp3aKO background, and that the expression of CYP3As on the CYP3A-HAC was maintained through the generations.
Protein expression and enzymatic activities in the livers and intestines
To determine the protein expression of human CYP3A derived from the livers and intestines of CYP3A-HAC/Cyp3aKO mice, western blot analyses and metabolic analyses were carried out (Fig. 3B ). Western blot analyses using the anti-CYP3A antibody showed that the expression of human CYP3A and mouse Cyp3a proteins was detected in the livers and intestines of CYP3A-HAC/Cyp3aKO mice and WT mice, respectively, but not in those of Cyp3aKO mice Human Molecular Genetics, 2013, Vol. 22, No. 3 581 (Fig. 3B ). After treatment with PCN, the expression of human CYP3A and mouse Cyp3a proteins was remarkably increased in the livers of CYP3A-HAC/Cyp3aKO mice and WT mice, respectively, but not in those of Cyp3aKO mice. To examine whether the CYP3A proteins expressed in the livers and intestines of CYP3A-HAC/Cyp3aKO mice were functional, the metabolites formed by CYP3A, a-OH triazolam (TRZ) and 4-OH TRZ were determined as markers of CYP3A activities ( Fig. 3C and D) . a-OH TRZ and 4-OH TRZ were detected in the liver and intestinal microsomes of WT mice and CYP3A-HAC/Cyp3aKO mice, but were markedly low in those of Cyp3aKO mice. CYP3A activities in the liver microsomes of CYP3A-HAC/Cyp3aKO mice were 30-50% of those observed in humans and WT mice, and the activities in the intestinal microsomes were comparable with those in humans and WT mice, which was correlated with the data of protein expression by western blot analyses (Fig. 3B) . Furthermore, immuno-inhibition assays using a human CYP3A4 antibody showed that the anti-human CYP3A4 antibody did not inhibit TRZ metabolism in the liver and intestinal microsomes of WT mice, and that the antibody inhibited TRZ metabolism in the liver and intestinal microsomes of CYP3A-HAC/Cyp3aKO mice, which was consistent with results in humans (Supplementary Material, Fig. S7 ). These data suggest that human CYP3A protein(s) derived from the livers and intestines of CYP3A-HAC/ Cyp3aKO mice were functional, and that CYP3A-specific metabolic activities in the livers and intestines of CYP3A-HAC/ Cyp3aKO mice were mediated by human CYP3A protein(s) expressed from CYP3A gene(s) on the CYP3A-HAC.
Kinetics of TRZ metabolism
The kinetics of TRZ metabolism were analyzed to assess whether the enzymatic properties of CYP3A introduced in the CYP3A-HAC/Cyp3aKO mice were the same as that in humans. Michaelis -Menten plots of TRZ metabolism in the liver and intestinal microsomes of WT mice, CYP3A-HAC/Cyp3aKO mice and humans are shown in Figure 4A -C, respectively, and the kinetic parameters for TRZ metabolism are listed in Supplementary Material, Table S3 . In the liver microsomes of WT mice, formation of 4-OH TRZ obeyed a conventional Michaelis -Menten kinetic model. However, formation of a-OH TRZ did not obey a conventional Michaelis -Menten kinetic model but could be fitted with the Michaelis -Menten kinetic model with a noncompetitive substrate inhibition model (Fig. 4B ). In contrast, formation of a-OH TRZ and 4-OH TRZ in the liver 
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Human Molecular Genetics, 2013, Vol. 22, No. 3 microsomes of CYP3A-HAC/Cyp3aKO mice could be fitted with the conventional Michaelis -Menten kinetic model, which was consistent with those in human livers ( Fig. 4A and C). At low concentrations of TRZ, formation of a-OH TRZ was remarkably higher than formation of 4-OH TRZ in the liver microsomes of WT mice, whereas almost identical formation rates of a-OH TRZ and 4-OH TRZ were observed in the liver microsomes of CYP3A-HAC/Cyp3aKO mice and humans. In addition, K m values for both pathways in the liver microsomes of CYP3A-HAC/Cyp3aKO mice and humans were much higher than those in WT mice ( Fig. 4D ; Supplementary Material, Table S3 ). In contrast, the ratios of intrinsic clearance (V max /K m ) for a-OH TRZ and 4-OH TRZ formations in the liver microsomes of CYP3A-HAC/ Cyp3aKO mice and humans were 3-fold lower than those in WT mice (2.73 and 2.61 versus 8.39, respectively) (Fig. 4E ). These data suggest that the kinetics of TRZ in the liver and intestinal microsomes of CYP3A-HAC/Cyp3aKO mice were very similar to those of humans, but not to those of mice.
MBI effects of CYP3A inhibitors on CYP3A activity
To assess whether CYP3A-HAC/Cyp3aKO mice are useful for predicting clinical DDIs induced by CYP3A-mediated MBI, we investigated the time-dependent inactivation effects of representative CYP3A inhibitors (erythromycin, clarithromycin and diltiazem) upon CYP3A activity in the liver microsomes of CYP3A-HAC/Cyp3aKO mice compared with those of humans and WT mice ( Fig. 4F-H) . Formation of 4-OH TRZ was used as a marker of CYP3A activity. Erythromycin and clarithromycin showed strong time-dependent inactivation effects on CYP3A activity in the liver microsomes of CYP3A-HAC/Cyp3aKO mice as well as in humans, but exhibited very weak time-dependent inactivation effects in the liver microsomes of WT mice, as described in our previous report (30) . In contrast, diltiazem showed weaker time-dependent inactivation effects on CYP3A activity in the liver microsomes of CYP3A-HAC/Cyp3aKO mice and humans than in WT mice. These species-specific in vitro MBI effects in the liver were also observed in the intestine (data not shown). These data suggested that the CYP3A enzyme from the CYP3A-HAC/ Cyp3aKO mice was 'humanized', and that the CYP3A-HAC/ Cyp3aKO mice may be useful for predicting clinical DDIs.
CYP3A7-specific metabolites
To ascertain whether CYP3A7 expressed in CYP3A-HAC/ Cyp3aKO fetal livers was functional, a typical metabolite formed by CYP3A7, 16-hydroxydehydroepiandrosterone (16a-OH DHEA) (5), was quantified after the incubation of DHEA and microsomes (Fig. 5A -F) . DHEA was incubated with CYP3A-HAC/Cyp3aKO adult mouse liver microsomes (HAC/KO_ALM), CYP3A-HAC/Cyp3aKO fetal mouse liver microsomes (HAC/KO_FLM), WT adult liver microsomes (WT_ALM) and WT fetal liver microsomes (WT_FLM). A remarkably high level of 16a-OH DHEA was observed in the sample incubated with HAC/KO_FLM (Fig. 5D) .
A remarkably low level of 16a-OH DHEA was observed in other samples incubated with WT_FLM, WT_ALM or HAC/ KO_ALM (Fig. 5C, E and F) . Furthermore, quantitative analyses using DHEA hydroxylase assays showed that the 16a-OH DHEA concentration in HAC/KO_FLM was approximately 15 times higher than that in WT_FLM (Fig. 5G) . The concentration was rarely detected in WT_ALM and HAC/ KO_ALM. Quantification analyses of protein expression showed that adult-specific CYP3A4 was expressed in HAC/ KO_ALM and pooled human adult liver microsomes (HLM), and that fetal-specific CYP3A7 was expressed in only HAC/KO_FLM (Fig. 5H) , which was correlated with the data of mRNA expression determined by RT-PCR (Fig. 2E) . Very similar results were confirmed using the liver microsomes from CYP3A-HAC/WT mice with mouse Cyp3a genes (Supplementary Material, Fig. S8 ), suggesting that disruption of Cyp3a did not affect DHEA metabolism. These results were comparable with those detailed in recent 
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Human 31) . These data suggest that the CYP3A7 protein was expressed in the livers of Tc fetuses, and that CYP3A7 was functional in vitro.
DISCUSSION
We successfully generated genomically and functionally humanized CYP3A mice in the present study. The most significant feature was that we achieved germline transmission of the CYP3A-HAC. Although the hChr.14-based HAC vector used in the present study was transmitted through a germline (29) , larger regions on hChr.7, including the CYP3A gene cluster cloned into the HAC vector (DAF006752-HAC), were not transmitted through a germline. However, smaller regions on hChr.7, including the CYP3A gene cluster cloned into the HAC vector (CYP3A-HAC), were transmitted through a germline, showing that harmful genes affecting development may be present in the region between AF006752 and AC073842 on hChr.7. CYP3A-HAC mice carrying all of the human CYP3A genes were further transferred into a mouse Cyp3a KO background designed as CYP3A-HAC/Cyp3aKO mice.
Several transgenic humanized CYP3A lines have been generated by other groups, using genomic clones such as bacterial artificial chromosome (BAC), or tissue-specific or conditional promoter-driven CYP3A cDNA. Granvil et al. (12) reported that CYP3A4 was not expressed after 6 weeks in the livers of BAC transgenic male mice containing the CYP3A4 genomic region even if the integrated copy number of the transgene was predicted to be 5, possibly because of the lack of a cis-acting binding site, or because of the positional effect of the integrated transgene. Furthermore, CYP3A4-BAC transgenic mice showed a lactation defect caused by abnormal homeostasis of estradiol (32) . In our study, CYP3A4 was expressed in the livers of male CYP3A-HAC mice even after 6 weeks, and the pups from the mothers with CYP3A-HAC were healthy, suggesting that the mother with CYP3A-HAC did not show a lactation defect. Li et al. (11) detailed the generation of transgenic mice lines containing CYP3A7 cDNA with mouse metallothionein promoters in which CYP3A7 was translated into a catalytically active enzyme . The CYP3A7 transgenic mouse lines showed that several copy numbers were integrated into the mouse genome and that an exogenous promoter was used to express CYP3A7. Therefore, the expression in the CYP3A7 transgenic mice did not always reflect that of humans. In the present study, the expression of CYP3A7 protein in CYP3A-HAC mice was higher in the fetal stages, and CYP3A7 was functional in vitro, suggesting that developmental CYP3A7 expression was, in a physiological sense, similar to that in humans.
The humanized CYP3A transgenic mice described above had a mouse Cyp3a genetic background. Recently, van Herwaarden et al. (16) reported the generation of Cyp3a KO mice expressing human CYP3A4 in the intestine or liver with tissue-specific promoters. The expression of human CYP3A4 in the intestine of Cyp3a KO mice with intestinespecific CYP3A4 dramatically decreased the absorption of docetaxicel into the bloodstream. However, the induction of the CYP3A gene and the level of gene expression cannot be regulated physiologically in the transgenic mouse lines because exogeneous promoters were used for the expression of the CYP3A4 gene. The most critical problems in the method to generate transgenic mice described above are that the integration site and integrated copy number of the transgene cannot be controlled, which may result in unpredictable and non-physiological expression in the transgenic mice.
To overcome these problems, Hasegawa et al. (33) reported the generation of new humanized CYP3A mice lacking the endogenous Cyp3a cluster excluding Cyp3a13, but with the insertion of a BAC containing CYP3A4 and CYP3A7 into the KO site. Although an 800 kb genomic segment including the mouse Cyp3a cluster was deleted in the mice, only the 125 kb genomic segment including human CYP3A4 and CYP3A7 was inserted in the mice. The genomic CYP3A cluster on the HAC contained not only CYP3A4, CYP3A5, CYP3A7 and CYP3A43 genes (34), but also pseudogenes such as CYP3AP1, CYP3AP2 and CYP3AP3, their essential regulatory regions [including promoters and enhancers (35, 36) ], non-coding microRNA-responsive elements (37, 38) and unknown elements affecting the expression of CYP3As. Although the BAC-transgenic approach containing genomic regions is a powerful tool for generating humanized mice, upstream or downstream regions of the desired gene cluster cannot be selected due to the use of a pre-existing BAC library, suggesting that gene-control elements (including enhancers or promoters) may not be included. In the present study, using HAC technology, the human CYP3A genes in Tc mice were regulated in copy number, inserted as desired large genomic regions and maintained independently as a single chromosome in the mouse genome, which enabled human-like expression patterns in the CYP3A-HAC mice. The present study showed that the CYP3A-HAC contains cis-acting binding sites, and that a megabase-sized gene cloning system using the HAC vector enabled appropriate tissue-specific and developmental-specific transcriptional expression of human CYP3A genes in Tc mice despite the human origin of CYP3A cloned into the HAC, as we observed previously (21, 39) . Thus, CYP3A-HAC/Cyp3aKO mice may overcome the potential problem in the previously developed transgenic mice. Although the CYP3A-HAC/Cyp3aKO mouse line might be a more reliable in vivo model than WT animals and available CYP3A-transgenic mouse lines for the prediction of human pharmacokinetics (including the potential of clinical DDIs mediated by CYP3A), we need to show in vivo data using CYP3A-HAC/Cyp3aKO mice and to compare them with several transgenic mouse lines for the next step.
The CYP3A activity in the liver microsomes of CYP3A-HAC/Cyp3aKO mice was 40% that of the HLM. CYP3A-HAC/Cyp3aKO mice have a single chromosome of the CYP3A-HAC, although normal humans have two chromosomes of hChr.7 containing a CYP3A cluster. Mice containing two copies of the CYP3A-HAC are predicted to show the similar expression level as that of humans. Although all known polymorphisms in the CYP3A cluster were not investigated, CYP3A4 and CYP3A7 on the HAC are speculated to be the WT gene since both genes showed the normal expression pattern and enzymatic activity in this study. Expression levels of CYP3As in the human population are variable (40) , so mice showing variable expression levels of CYP3As can be generated by transferring several copies of the CYP3A-HAC.
Some CYP genes are induced idiosyncratically by certain xenobiotics. Species-specific differences of such enzyme induction have been observed. For example, the antibiotic rifampicin induces CYP3A in humans and rabbits, whereas PCN induces CYP3A in rodents (41, 42) . In the present study, PCN induced 4-fold higher human CYP3A4 expression in CYP3A-HAC mice than rifampicin, which was consistent with a previous study (27) . This property is due to the species origin of the nuclear receptor PXR, which is the determining factor for ligand specificity (41, 42) . Thus, the next step is to generate CYP3A-HAC/Cyp3aKO mice with humanized PXR for induction studies.
The HAC can carry multiple genes and large size of genes, and can be transmitted through a germline and maintained stably in vivo. Hence, it would be useful to generate a mouse model containing large-sized, drug metabolizing enzyme-related and species-specific genes, such as not only the CYP3A cluster but also the UGT1 gene ( 250 kb), UGT2 cluster (1.5 Mb), CYP2C cluster ( 400 kb), HLA cluster (3 Mb) and MDR1 gene ( 250 kb). It is very advantageous that the same HAC can be transferred to various species, e.g. rat and monkey, via ES cells. Rats are more important and more popular experimental animals than mice when evaluating human-use drugs. Since transgenic rats were produced from rat ES cell-transfected Kusabira-orange gene (43), we may be able to generate Tc rats containing the CYP3A-HAC constructed in this study. Taken together, CYP3A-HAC/Cyp3aKO mice could be a useful model not only for the elucidation of the mechanism in the tissueand stage-specific expression of CYP3A genes, but also for the prediction of idiosyncratic human toxicities and pharmacokinetics (including the potential for clinical DDIs mediated by CYP3A).
MATERIALS AND METHODS
Plasmid construction
Targeting vectors were constructed as follows. For pBS-TEL/ AF006752 Puro, a PCR product from AF006752 (NT_007933, 39 620 017 -39 659 856) was amplified by PCR with the primers AF006752-L/AF006752-R (5.3 kb), digested with BamHI (5.3 kb) and sub-cloned into the BamHI sites of the pBS-TEL/Puro vector (17) . For pAC004922-loxP-Hyg, Table S1 .
Cell culture
A CYP3A-HAC was constructed using a previously described megabase-sized gene-cloning system (17) . Chicken DT40 cells containing hChr.7 were maintained at 408C in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 1% chicken serum, 50 mM 2-mercaptoethanol and 1.5 mg/ml G418 (44) . CHO-K1 cells used as fusion recipients for chromosome transfer were maintained at 378C in Ham's F-12 nutrient mixture (Invitrogen, Carlsbad, CA, USA) supplemented with 10% FBS. Mouse embryonic fibroblasts (MEFs) were isolated from 13.5 days post-coitum embryos. A9 cells, MEFs and tail fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM) (Sigma-Aldrich, St Louis, MO, USA) plus 10% FBS. Parental mouse ES cell lines, TT2F and microcell hybrid clones were maintained on mitomycin C (Sigma -Aldrich)-treated Jcl:ICR (CLEA Japan, Tokyo, Japan) MEFs as feeder layers in DMEM with 18% FBS (Hyclone), 1 mM sodium pyruvate (Invitrogen), 0.1 mM non-essential amino acids (Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma-Aldrich), 2 mM L-glutamine (Invitrogen) and 1000 U/ml leukemia inhibitory factor (Funakoshi, Tokyo, Japan).
Modification of hChr.7 and construction of the CYP3A-HAC in DT40 cells
Homologous recombination-proficient chicken DT40 cells (1 × 10 7 ) were collected in 0.5 ml of RPMI with 25 mg of linearized targeting vector and electroporated at 550 V and 25 mF using a Gene Pulser apparatus (Bio-Rad, Hercules, CA, USA). Drug-resistant DT40 clones were selected in 1.5 mg/ml G418, 0.3 mg/ml puromycin, 1.5 mg/ml hygromycin or 0.5 mg/ml L-histidinol. Homologous recombination in DT40 hybrid clones was identified by PCR and Southern blot analyses as follows. DT40 clones containing the hChr.14-derived SC20-HAC (R56 clone) were maintained in 15 mg/ml blasticidin S. The loxP site for cloning the chromosomal fragment was previously inserted into SC20-HAC containing several genes in the R56 clone (17) . R56 and DT40 (hChr.7-DAF006752-loxP) were fused, and the DT40 cell hybrid containing the two human chromosomes maintained in 15 mg/ml blasticidin S and 1.5 mg/ml hygromycin. Finally, hybrid cells were transfected with a Cre-recombinase expression vector, pBS185 (Invitrogen), and the site-specific chromosomal reciprocal translocation between the defined hChr. 7 region and the HAC was confirmed by PCR and FISH analyses after sorting GFP-positive cells. The modified chromosomes (DAF006752-HAC) were transferred to CHO cells via MMCT. The DAF006752-HAC was transferred to DT40 cells via MMCT and modified as described above to construct CYP3A-HAC.
KO of the Cyp3a cluster in mouse ES cells
Cre-loxP-mediated large-gene deletion was done as described previously (17) . ES cells were transfected with the linearized loxP3aUP targeting vector and selected with G418 (250 mg/ml). The correctly targeted clones with the loxP3aUP were transfected with the linearized loxP3aDOWN targeting vector and selected with puromycin (0.6 mg/ml). Homologous recombination in the drug-resistant ES clones was identified by Southern blot analyses as follows. Then, the Cre expression vector, pBS185 (Invitrogen), was transfected into the double-loxP-targeted clone, and GFP-positive cells were sorted to collect the Cyp3a57-59 deleted clones. The GFP-positive clones were analyzed by PCR analyses to confirm the site-specific recombination as follows. For Cyp3a13 targeting, ES cells were transfected with the linearized loxP3a13 targeting vector, selected with G418 (250 mg/ml) and analyzed by PCR and Southern blot analyses.
Microcell-mediated chromosome transfer
MMCT was done as described previously (21) . DT40 cells containing the DAF006752-HAC or CYP3A-HAC were transferred to CHO cells by MMCT. CHO cells containing the HAC were used as donor microcell hybrids. Briefly, mouse ES cells were fused with microcells prepared from donor hybrid, CHO (DAF006752-HAC) or CHO (CYP3A-HAC) cells, and selected with G418 (250 mg/ml). The transferred HAC in each line was characterized by PCR and FISH analyses.
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Genomic PCR analyses
Genomic DNA was extracted from cell lines and Tc mouse tissue specimens, using a genomic extraction kit (Gentra System, Minneapolis, MN, USA), and PCR was performed using the following primers. Primer pairs for the detection of the region of the human CYP3A cluster were CYP3A4-4L/ CYP3A4-3R (CYP3A4), CYP3A5F/CYP3A5R (CYP3A5) and CYP3A7-3L/CYP3A7-3R (CYP3A7). Primer pairs for the detection of the region of the HAC were AL157858-F/ AL157858-R and AL121612-F/AL121612-R. The primer pairs for the detection of the targeting of pAC004922-loxP-Hyg at the AP001657 locus were p450loxP14L/Hyg244 (5.0 kb) and PGK2/p450loxP16R (5.0 kb). The primer pairs for the detection of the Cre-loxP-mediated chromosomal translocation between the HAC and modified hChr.7 were PGK1/GFP1 and PGK2/ GFP2. The primer pairs for the detection of the chromosome truncation at the AC073842 locus were hisD2/PT2R. The primer pairs for the detection of the deletion between Cyp3a57 and Cyp3a59 were PGK2/GFP2 and 3a25Fw/ 3a25Rv. The primer pairs for the detection of the deletion of Cyp3a13 were neo3-1/3 ′ genome 2 and 5 ′ down/3 ′ genome 2. The primer sequences for the genomic PCR analyses are described in Supplementary Material, Table S1 . Primer sets for the genotyping of Cyp3a57-59KO, Cyp3a13KO and Cyp3aKO (double-KO of Cyp3a57-59 and Cyp3a13) are described in Supplementary Material, Table S2 . DT40, CHO-K1, TT2F and normal mouse tissues were used as negative controls.
Southern blot analyses
Digested DNA samples were separated on a 0.8% agarose gel by electrophoresis and transferred to a Hybond N+ membrane (Amersham, Buckinghamshire, UK) in an alkaline solution. The membrane was hybridized overnight at 658C with 32 P-labeled probes and washed three times at 658C in 0.1% SSC for 30 min, and 0.1% SDS for 2 × 30 min. Radioactivity was visualized by scientific imaging film (Kodak, Tokyo, Japan). Primer pairs for the probe in the pBS-TEL/AF006752 Puro clones, pAC004922-loxP-Hyg clones and loxP3aUP clones were PSF11/PSR11, NPp6L/NPp6R and 3aYL/3aYR, respectively. About 700 bp of the GFP-coding region was used to probe for the loxP3aDown clones. Primer pairs for the probe in the loxP3a13 clones were 3a13-3 ′ probe3Fw/3a13-3 ′ probe3Rv2 (3 ′ probe). The primer sequences for the probe are described in Supplementary Material, Table S1 .
FISH analyses
The tissue samples were homogenized and incubated for 15 min in 0.075 M KCl, fixed with methanol and acetic acid (3:1), and then slides were prepared using standard methods. FISH analyses were performed using fixed metaphase or interphase spreads of each cell hybrid, using digoxigenin-labeled (Roche, Basel, Switzerland) human COT-1 DNA (Invitrogen) and biotin-labeled DNA (PGK-Puro and PGK-Hygro), essentially as described previously (21) . Chromosomal DNA was counterstained with DAPI (Sigma -Aldrich). To confirm a recombination of the CYP3A cluster on hChr.7 to the hChr.14-derived HAC, two-color FISH using hChr.14-and hChr.7-specific probes (Takara) was used according to manufacturer instructions. Images were captured using the NIS-Elements system (Nikon, Tokyo, Japan) or the Argus system (Hamamatsu Photonics, Tokyo, Japan).
Generation of chimeric mice and Tc mice
Chimeric mice were produced from the 10 ES (DAF006752-HAC) and 3 ES (CYP3A-HAC) cell lines for the Tc line. Chimeric mice were produced from one Cyp3a57-59KO ES and five Cyp3a13KO ES cell lines for the Cyp3aKO lines. Chimera production was completed as described previously (21) . Briefly, ES cells were injected into eight-cell-stage embryos derived from ICR mice (CLEA, Tokyo, Japan) and then transferred into pseudopregnant ICR females. Three to five chimeric mice showing 100% coat-color chimerism were used to generate germlinetransmittable mice in each line. Three to five mice were used in RT-PCR, FISH and enzymatic functional assays. Representative data are shown in each figure. All animal experiments were approved by the Animal Care and Use Committee of Tottori University and Chiba University.
RT-PCR analyses
Total RNA from Tc tissue specimens was prepared using ISOGEN (Nippon Gene, Tokyo, Japan) and purified using RNeasy columns (Qiagen, Hilden, Germany), in accordance with manufacturer instructions, and then treated with RNasefree DNase I (Wako Pure Chemicals, Osaka, Japan). First-strand cDNA syntheses were completed using random hexamers and SuperScript III reverse transcriptase (Invitrogen). Primer pairs for the detection of the expression of human CYP3A genes were as follows: for CYP3A4, 3A4-2L/3A4-2R; for CYP3A5, 3A5-1L/3A5-1R; for CYP3A7, 3A7-1L/3A7-1R; for CYP3A43, 3A43-2L/3A43-2R. Primer pairs for the detection of the expression of mouse Cyp3a genes and Gapdh were as follows: for Cyp3a11, 3a11-1L/3a11-1R; for Cyp3a13, 3a13-2L/3a13-2R; for Cyp3a57, 3a57-847F/3a57-1088R; for Cyp3a44, 3a44-2L/3a44-2R; for Cyp3a25, 3a25-2L/3a25-2R; for Cyp3a59, 3a59-848F/3a59-1027R; for Gapdh, RPC1/2. Gapdh was used as an internal control. The primer sequences for the RT-PCR analyses are described in Supplementary Material, Table S1 . cDNAs from C57BL/6 mouse tissues were used as controls. PCR was completed with cDNA, using ExTaq (Takara Bio, Shiga, Japan) or AmpliTaq Gold (Perkin Elmer, Waltham, MA, USA). Amplifications were undertaken with an annealing temperature of 56-628C for 25 -43 cycles. Amplified fragments were then resolved by electrophoresis on 2% agarose gel, followed by staining with ethidium bromide.
Treatment of CYP3A inducers
Pregnenolone 16a-carbonitrile (PCN; Sigma -Aldrich), clotrimazole (Clo; Sigma -Aldrich) and rifampicin (Rif; SigmaAldrich) were used as typical CYP3A inducers. These were dissolved in corn oil (Sigma -Aldrich) and administered (i.p.) to mice at 100 mg/kg for 4 days.
Preparation of microsomes from the liver and intestine
Pooled human liver microsomes prepared from 20-30 donors were purchased from BD Gentest (Woburn, MA, USA). Pooled human intestinal microsomes prepared from 18 donors were purchased from Xenotech (Lenexa, KS, USA). Liver tissues from mice were homogenized in ice-cold 1.15% KCl and microsomes were isolated by differential centrifugation as described previously (45) . Briefly, liver homogenate was centrifuged at 9000g for 20 min at 48C. The resultant supernatant was then ultra-centrifuged at 105 000g for 1 h at 48C. The microsomal pellet was washed and resuspended in 100 mM sodium phosphate buffer (pH 7.4) and stored at -808C until analyses. Extraction of intestinal microsomal fractions was adapted from previous reports (46, 47) . After excision of the small intestine, a 10 cm segment of the upper part of the small intestine was immediately placed on an ice-cold stainless dish and cut longitudinally and then washed with ice-cold phosphate-buffer saline (PBS) by gentle swirling. The cut segment of small intestine was placed on ice-cold PBS (pH 7.2) containing 1.5 mM EDTA, 3 U/ml heparin and 0.5 mM dithiothreitol for 20 min to loosen mucosal cells. Subsequently, the mucosal cells were scraped off with a micro cover glass and centrifuged at 2000g for 10 min at 48C. The centrifuged mucosal cells were added to four volumes of ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM KCl, 1 mM EDTA, 1 mg/ ml trypsin inhibitor, protease cocktail inhibitor (Calbiochem, La Jolla, CA, USA) and 20% (v/v) glycerol and then homogenized using a motor-driven Teflon-tipped pestle (five strokes at 1200 r.p.m.). The homogenates were centrifuged at 9000g for 20 min at 48C, and the resultant supernatant centrifuged at 105 000g for 1 h at 48C. The microsomal pellet was washed, resuspended in 250 mM sucrose and stored at -808C until analyses. Protein concentrations were determined using a DC protein assay kit (Bio-Rad) or a BCA protein assay kit (Thermo Scientific) according to manufacturer instructions.
Western blot analyses
Microsomal fractions (10 mg) of livers and small intestines were separated by 10% SDS -polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. After a 30 min-incubation with blocking buffer (0.05% Tween 20 in PBS containing 3% BSA), the membrane was probed for 1 h at room temperature using polyclonal goat anti-rat CYP3A2 (BD Gentest), which can detect human CYP3A. Monoclonal mouse anti-human b-actin (Sigma -Aldrich), which can detect mouse b-actin, was used as the primary antibody of the internal control for sample loading. The primary antibody was diluted 1000-fold or 3000-fold in 0.05% Tween 20 in PBS containing 3% BSA for anti-rat CYP3A2 antibody or antihuman b-actin antibody, respectively. After washing, the membrane was incubated with peroxidase-conjugated secondary antibody for 1 h at room temperature. The secondary antibodies used were anti-goat IgG (Sigma -Aldrich) and anti-mouse IgG (Sigma -Aldrich) for anti-rat CYP3A2 and anti-human b-actin antibodies, respectively, and were diluted 5000-fold with 0.05% Tween 20 in PBS containing 3% BSA. The expression of CYP3A and b-actin proteins was consequently detected by an enhanced chemiluminescence method using ECL TM western blotting detection reagent (GE Healthcare, Buckingham, UK) and LAS-1000plus (Fujifilm, Tokyo, Japan).
Assay of TRZ-hydroxylase activity TRZ was purchased from Wako Pure Chemicals. a-Hydroxy TRZ (a-OH TRZ) and 4-hydroxy TRZ (4-OH TRZ) were supplied by Nihon Upjohn Co. (Tokyo, Japan). TRZ-hydroxylase activity was determined as described previously (45) . Briefly, the basic incubation mixture contained liver or intestinal microsomes, 0.1 mM EDTA, 100 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (0.5 mM NADP + , 2 mM glucose-6-phosphate, 1 IU/ml glucose-6-phosphate dehydrogenase, 4 mM MgCl 2 ) and substrate (200 mM TRZ), in a final volume of 250 ml. The concentrations of microsomal proteins and incubation times used were selected from the linear range of metabolite formation for TRZ-hydroxylase activity. The mixtures were preincubated for 1 min at 378C, and reactions initiated by the addition of 25 ml of the NADPH-generation system. Incubation was stopped by the addition of 100 ml of acetonitrile, followed by the addition of 50 ml of 1 mg/ml oxazepam in methanol for TRZ-hydroxylase activity as an internal control. Determination of a-OH TRZ and 4-OH TRZ was carried out using a Hitachi L-7000 model HPLC system (Tokyo, Japan) consisting an L-7400 UV detector and a CAPCELL PAK C18 UG120 column (4.6 mm × 250 mm, 5 mm; Shiseido, Tokyo, Japan). The mobile phase consisted of 10 mM potassium phosphate buffer (pH 7.4), acetonitrile and methanol (60/30/10, v/v/v), with a flow rate of 1.0 ml/min. The eluent was monitored at a wavelength of 220 nm.
Kinetics of TRZ metabolism
Liver microsomes (0.1 mg/ml) or intestinal microsomes (0.25 mg/ml) of WT mice, PCN-treated CYP3A-HAC/ Cyp3aKO mice or humans were incubated with several concentrations of TRZ (25 -750 mM) in the presence of an NADPH-generating system at 378C in a final volume of 250 ml. Incubation times were 20 min or 30 min for liver or intestinal microsomes, respectively. Formation of a-OH TRZ and 4-OH TRZ was determined by HPLC as described above. Kinetic parameters for the formation of a-OH and 4-OH TRZ (V max , K m and K s ) were determined by a nonlinear least-squares method, using DeltaGraph 5 (Red Rock Software, Salt Lake, UT, USA) according to the equations described below. The kinetics of the formation of a-OH TRZ and 4-OH TRZ in the liver and intestinal microsomes of humans and CYP3A-HAC mice were analyzed by a conventional Michaelis -Menten kinetic model (equation 1):
For WT mice, the data of 4-OH TRZ in liver microsomes and a-OH TRZ and 4-OH TRZ in intestinal microsomes were also analyzed using equation (1), except that the data of a-OH TRZ in the liver microsomes of WT mice were analyzed by the Human Molecular Genetics, 2013, Vol. 22, No. 3 589
Michaelis-Menten kinetic model with a non-competitive substrate inhibition model, as described previously (48) (equation 2):
Immuno-inhibition of TRZ metabolism
The immuno-inhibition assay of TRZ metabolism was achieved by preincubation of liver or intestinal microsomes (25 mg) of WT mice, CYP3A-HAC/Cyp3aKO mice, or humans in the presence or absence of the specific antibody raised against human CYP3A4 (2.5 ml; BD Gentest) for 10 min at room temperature in a final volume of 25 ml. The preincubation mixtures were then diluted with a reaction mixture containing 200 mM TRZ, and the reactions were started by the addition of the NADPH-generating system in a final volume of 250 ml. Samples were incubated for an additional 20 min at 378C.
MBI effects of CYP3A inhibitors in liver microsomes
Liver microsomes of CYP3A-HAC/Cyp3aKO mice, humans or WT mice (0.1 mg/ml) were preincubated at 378C with various concentrations of inhibitors. Each reaction mixture contained an NADPH-generating system. At various time points, the stock of TRZ (2 ml of 25 mM TRZ in methanol) was added to the preincubation mixture and incubated for a further 10 min to measure the remaining catalytically active CYP3A. The reaction was terminated by the addition of acetonitrile, and formation of 4-OH TRZ was determined by HPLC. Data were corrected for loss of activity in the control incubation (no inhibitor) at each time point.
Identification of DHEA metabolites and DHEA hydroxylase assays 16a-OH DHEA was formed from the parent compound (DHEA) using the following method. A baculovirus expression system was used as a CYP3A7 standard (BD Gentest; BD Biosciences). A reaction mixture containing 0.01 mM DHEA, 0.5 mg/ml mouse liver microsomes and 87.5 mM potassium phosphate buffer (pH 7.4) was pre-incubated at 378C for 5 min. After preincubation, the reaction was initiated by the addition of an NADPH-generating system (6 mM MgCl 2 , 33 mM b-NADP + , 8 mM glucose-6-phasphate, 10 IU/ ml glucose-6-phosphate dehydrogenase). After 20 min of incubation at 378C, the reaction was stopped by the addition of cold acetonitrile containing 0.5 mM androsterone as an internal standard. After centrifugation, the supernatant was used for analyses. LC-MS/MS analyses were carried out using a Prominence UFLC LC-20A system (Shimadzu, Kyoto, Japan) and the API5000 (Applied Biosystems/MDS Sciex, Toronto, Canada) equipped with an electrospray ionization (ESI) source. Qualitative verification of DHEA metabolites against standards was completed using an L-column ODS 2.1 mm I.D. × 150 mm (5 mm). A 10 ml aliquot of each analytical sample was injected onto the column and eluted using a mobile phase consisting of water containing 1% formic acid (mobile phase A) and 1% formic acid in acetonitrile (mobile phase B) at a flow rate of 0.2 ml/min. A linear gradient of 25% B to 27.5% B over 10 min was followed by another gradient of 27% B to 100% B over the next 10 min, and finally the mobile phase was held at 25% B for 10 min. 16a-OH DHEA was detected by selected ion monitoring using m/z 287.2-269.2. This precursor ion (m/z 287.2) was an in-source fragment [M + H-H 2 O] + ion that was the most abundant ion observed in ESI-MS for the hydroxylated DHEA metabolites. The metabolite was quantified by comparing the peak area of each analyte to that of the internal standard, using an ion transition of m/z 291.2 to 273.2.
Quantification of the expression of CYP3A proteins
The pretreatment was done as follows. Calibration samples were prepared from WT mouse liver microsomes spiked with expressed CYP3A4 and CYP3A7. Each microsome (10 ml, 0.1 mg/ml) was digested by trypsin after reduction and blocking of cysteine. After digestion, these samples were extracted using the OASIS HLB mElution plate (30 mm; Waters Corporation, Milford, MA, USA). LC-MS/ MS analyses were done as follows. CYP3A4 and CYP3A7 were analyzed on the QTRAP 5500 (AB SCIEX, Concord, Canada) coupled with an LC-20A series HPLC system (Shimadzu). SIR ion transition channels for the quantification of CYP3A4 and CYP3A7 were as follows: CYP3A4: 564.3 745.9, CYP3A7: 823.2 1091.5.
A CADENZA CD-C18 column (flow rate: 0.2 ml/min, 150 × 2.0 mm ID, 3 mm Imtakt, Kyoto, Japan) was used for this analysis in a gradient program. Absolute protein quantification (described in Supplementary Material, Fig. S8 ) was done as described previously (49, 50) .
Statistical analysis
Data are presented as means + SD. Statistical analyses were performed using Statcel (OMS, Tokyo, Japan). Comparison of multiple groups was made by ANOVA followed by post hoc test of Scheffe's F. P , 0.05 was considered statistically significant.
